Who are Bevacizumab and Capecitabine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bevacizumab-and-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Bevacizumab and Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab and Capecitabine (Bevacizumab and Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy. Area: Oncology.

phase 3 Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy VEGF (bevacizumab); thymidylate synthase (capecitabine) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Bevacizumab and Capecitabine (Bevacizumab and Capecitabine) — Central European Cooperative Oncology Group. Bevacizumab inhibits tumor angiogenesis by blocking VEGF, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab and Capecitabine TARGET	Bevacizumab and Capecitabine	Central European Cooperative Oncology Group	phase 3	Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy	VEGF (bevacizumab); thymidylate synthase (capecitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: monoclonal antibody (anti-VEGF) and fluoropyrimidine chemotherapy class)

Central European Cooperative Oncology Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bevacizumab and Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/bevacizumab-and-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab